Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of “Buy” by Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have earned an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.17.

CNTA has been the topic of a number of recent analyst reports. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Oppenheimer restated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th.

Centessa Pharmaceuticals Stock Up 0.9 %

NASDAQ CNTA opened at $16.14 on Friday. The stock has a fifty day moving average of $15.48 and a 200-day moving average of $11.77. The stock has a market capitalization of $1.83 billion, a P/E ratio of -10.35 and a beta of 1.47. Centessa Pharmaceuticals has a 52 week low of $5.58 and a 52 week high of $17.59. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, equities research analysts forecast that Centessa Pharmaceuticals will post -1.68 EPS for the current year.

Insider Activity

In other news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 25,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total value of $375,000.00. Following the transaction, the insider now owns 223,369 shares of the company’s stock, valued at $3,350,535. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 325,031 shares of company stock valued at $5,213,043 in the last ninety days. 11.59% of the stock is currently owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of large investors have recently modified their holdings of the business. First Light Asset Management LLC boosted its position in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after acquiring an additional 1,778,515 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Centessa Pharmaceuticals by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after acquiring an additional 850,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after buying an additional 418,615 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after buying an additional 987,997 shares in the last quarter. Finally, Farallon Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after buying an additional 1,625,000 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.